Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Compass Therapeutics Inc (NASDAQ: CMPX) was $2.7 for the day, down -5.26% from the previous closing price of $2.85. In other words, the price has decreased by -$5.26 from its previous closing price. On the day, 1.01 million shares were traded. CMPX stock price reached its highest trading level at $2.835 during the session, while it also had its lowest trading level at $2.64.
Ratios:
Our analysis of CMPX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.33 and its Current Ratio is at 8.33. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.06.
On April 02, 2025, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform but kept the price unchanged to $6.
On February 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $12.Guggenheim initiated its Buy rating on February 24, 2025, with a $12 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 27 ’25 when Schuetz Thomas J. bought 10,000 shares for $2.11 per share. The transaction valued at 21,100 led to the insider holds 6,480,825 shares of the business.
GORDON CARL L sold 3,571,428 shares of CMPX for $5,678,571 on Apr 09 ’25. The Director now owns 0 shares after completing the transaction at $1.59 per share. On Apr 09 ’25, another insider, ORBIMED ADVISORS LLC, who serves as the Director of the company, sold 3,571,428 shares for $1.59 each. As a result, the insider received 5,678,571 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CMPX now has a Market Capitalization of 373361408 and an Enterprise Value of 253280496. For the stock, the TTM Price-to-Sale (P/S) ratio is 439.25 while its Price-to-Book (P/B) ratio in mrq is 3.39. Its current Enterprise Value per Revenue stands at 297.977 whereas that against EBITDA is -4.135.
Stock Price History:
The Beta on a monthly basis for CMPX is 1.29, which has changed by 1.6732674 over the last 52 weeks, in comparison to a change of 0.1116153 over the same period for the S&P500. Over the past 52 weeks, CMPX has reached a high of $4.08, while it has fallen to a 52-week low of $0.87. The 50-Day Moving Average of the stock is 18.78%, while the 200-Day Moving Average is calculated to be 26.82%.
Shares Statistics:
CMPX traded an average of 811.33K shares per day over the past three months and 901210 shares per day over the past ten days. A total of 138.28M shares are outstanding, with a floating share count of 87.95M. Insiders hold about 36.40% of the company’s shares, while institutions hold 43.16% stake in the company. Shares short for CMPX as of 1749772800 were 7389202 with a Short Ratio of 9.11, compared to 1747267200 on 6912500. Therefore, it implies a Short% of Shares Outstanding of 7389202 and a Short% of Float of 10.13.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Compass Therapeutics Inc (CMPX) is the result of assessments by 6.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.09 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.39 and -$0.56 for the fiscal current year, implying an average EPS of -$0.48. EPS for the following year is -$0.52, with 6.0 analysts recommending between -$0.25 and -$0.67.
